Silver-111

09/28/2023 - "Silver-111 is an attractive unconventional candidate for targeted cancer therapy as well as for single photon emission computed tomography and can be complemented by silver-103 for positron emission tomography noninvasive diagnostic procedures. "
08/03/2020 - "With a half-life of 7.45 days, silver-111 (βmax 1.04 MeV, Eγ 245.4 keV [Iγ 1.24%], Eγ 342.1 keV [Iγ 6.7%]) is a promising candidate for targeted cancer therapy with β- emitters as well as for associated SPECT imaging. "
02/01/2019 - "Calculation of productions of medical 201Pb, 198Au, 186Re, 111Ag, 103Pd, 90Y, 89Sr, 77Kr, 77As, 67Cu, 64Cu, 47Sc and 32P nuclei used in cancer therapy via phenomenological and microscopic level density models."
01/01/1989 - "Dose rate profiles in the tumor are calculated for potentially useful beta-emitting radionuclides, including 32P, 67Cu, 90Y, 111Ag, 131I, and 188Re, and for 193mPt, an emitter of conversion electrons and low-energy Auger electrons. "
10/01/1949 - "The use of radioactive silver for the detection of abscesses and tumors; the concentration of Ag111 in spontaneous and experimentally induced abscesses."

03/01/2008 - "Therefore, [111Ag]Ag-HA particles would be a potential therapeutic agent in the management of arthritis."
04/01/2023 - "111Ag is a radionuclide that can be generated by neutron capture on 110Pd and whose decay properties and production feasibility make it a potential therapeutic agent against arthritis. "

10/01/1949 - "The use of radioactive silver for the detection of abscesses and tumors; the concentration of Ag111 in spontaneous and experimentally induced abscesses."